Form 8-K - Current report:
SEC Accession No. 0001731122-25-000878
Filing Date
2025-06-13
Accepted
2025-06-13 17:30:36
Documents
13
Period of Report
2025-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6659_8k.htm   iXBRL 8-K 40404
2 EXHIBIT 10.1 e6659_ex10-1.htm EX-10.1 12063
  Complete submission text file 0001731122-25-000878.txt   223289

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avxl-20250610.xsd EX-101.SCH 3008
4 XBRL LABEL FILE avxl-20250610_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE avxl-20250610_pre.xml EX-101.PRE 22354
15 EXTRACTED XBRL INSTANCE DOCUMENT e6659_8k_htm.xml XML 3687
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 251047826
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)